Table 1 Demographic, clinical, radiological, and laboratory characteristics of the study population and comparison of the survived and dead patients
Characteristics | Total study population (n = 125) | Survived(n = 53) | Non-survived(n = 72) | p |
|---|---|---|---|---|
Age, mean ± SD | 67.9 ± 7.27 | 67.5 ± 7.27 | 68.2 ± 7.31 | 0.55 |
Sex, male, n (%) | 100 (80) | 42 (79.2) | 58 (80.6) | 1.00 |
Smoking, n (%) | 84 (67.2) | 32 (61.5) | 52 (72.2) | 0.25 |
Smoking packet-years, mean ± SD | 39.8 ± 35.0 | 34.6 ± 21.7 | 42.9 ± 40.8 | 0.32 |
Family history of IPF, n(%) | 8 (6.4) | 2 (3.8) | 6 (8.3) | 0.47 |
Comorbidities, n(%) | 70 (56) | 26 (49.1) | 44 (61.1) | 0.21 |
Diabetes mellitus, n(%) | 27 (21.6) | 8 (15.1) | 19 (26.4) | 0.19 |
Hypertension, n(%) | 28 (22.4) | 12 (22.2) | 16 (22.6) | 1.00 |
Cardiovascular disease, n(%) | 39 (31.2) | 14 (26.4) | 25 (34.7) | 0.34 |
COPD, n(%) | 15 (12) | 4 (7.5) | 11 (15.3) | 0.27 |
Lung cancer, n(%) | 6 (4.8) | 0 | 6 (8.3) | 0.04 |
Clubbing, n (%) | 26 (20.8) | 8 (15.4) | 18 (25) | 0.26 |
IPF exacerbation history | 8 (6.4) | 0 | 8 (11.1) | 0.02 |
Body mass index, kg/m2, mean ± SD | 27.9 ± 3.98 | 28.3 (3.32) | 27.6 (4.40) | 0.33 |
FVC, lt, mean ± SD | 2.35 ± 0.69 | 2.51 ± 0.75 | 2.23 ± 0.61 | 0.02 |
DLCO, mmol/kPa/min, mean ± SD | 3.96 ± 1.60 | 4.43 (2.67) | 3.11 (1.49) | < 0.001 |
Laboratory | ||||
Hemoglobin, g/dl, mean ± SD | 13.94 ± 1.43 | 13.8 ± 1.17 | 14.02 ± 1.6 | 0.48 |
Leucocytes, /mm3, median (IQR) | 8300 (2600) | 7950 (2975) | 8700 (2450) | 0.20 |
Neutrophils, /mm3, median (IQR) | 5250 (2050) | 4900 (1950) | 5550 (1950) | 0.21 |
Lymphocytes, /mm3, median (IQR) | 2100 (1000) | 2100 (775) | 2150 (1200) | 0.54 |
Platelets, /mm3, median (IQR) | 257,000 (92,500) | 237,000 (95,250) | 260,000 (95,500) | 0.17 |
CRP, mg/dl, median (IQR) | 0.47 (0.62) | 0.31 (0.70) | 0.58 (0.53) | 0.004 |
NLR, median (IQR) | 2.3 (1.7) | 2.32 (1.30) | 2.43 (1.89) | 0.70 |
PLR, median (IQR) | 119.4 (64.3) | 121.1 (58.2) | 118.2 (75.5) | 0.87 |
NLR, 1st year, median (IQR) | 2.5 (1.8) | 2.39 (1.4) | 2.75 (1.88) | 0.13 |
PLR, 1st year, median (IQR) | 130 (70.5) | 113.3 (54.0) | 136.7 (82.1) | 0.16 |
Biopsy proven disease, n(%) | 30 (24) | 18 (34) | 12 (16.7) | 0.03 |
HRCT, definite UIP pattern, n(%) | 92 (73.6) | 33 (62.3) | 59 (81.9) | 0.02 |
Honeycombing, n(%) | 93(74.4) | 34 (64.2) | 59 (81.9) | 0.04 |
Traction bronchiectasis, n(%) | 71 (56.8) | 22 (41.5) | 49 (68.1) | 0.004 |
Emphysema, n(%) | 19 (15.2) | 9 (17) | 10 (13.9) | 0.80 |
Home oxygen treatment, n(%) | 23 (18.4) | 1 (1.9) | 22(30.6) | < 0.001 |
Antifibrotic treatment | ||||
Pirfenidon, n(%) | 68 (54.4) | 26 (49.1) | 42 (58.3) | 0.37 |
Nintedanib, n(%) | 57 (45.6) | 27 (50.9) | 30 (41.7) | 0.37 |
Clinical progression, n(%) | 10 (8) | 3 (6.3) | 7 (10.1) | 0.52 |
Treatment cessation, n(%) | 24 (19.2) | 7 (14.6) | 18 (26.1) | 0.17 |
GAP stages II or III, n(%) | 75 (60) | 23 (43.4) | 52 (72.2) | 0.002 |